Fortress Biotech, Inc. (FBIO)

US — Healthcare Sector

Peers: MBIO ACHL APTO FBIOP CKPT ATXI PIRS ALRN RVPHW EYEN CGTX RNAZ KOD XOMAO ZIVO LUMO RVPH ATHA ACAD CABA

Automate Your Wheel Strategy on FBIO

With Tiblio's Option Bot, you can configure your own wheel strategy including FBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol FBIO
Rev/Share 2.1846
Book/Share 1.2282
PB 2.2468
Debt/Equity 3.3364
CurrentRatio 1.7225
ROIC -0.8891

MktCap 55887111.0
FreeCF/Share -2.6391
PFCF -0.8006
PE -1.2144
Debt/Assets 0.4169
DivYield 0
ROE -1.9597

Rating C-
Score 1
Recommendation Strong Sell
P/E Score 1
DCF Score 1
P/B Score 3
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

FBIO, FBIOP
Published: May 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl) Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl)

image for news Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

New Strong Sell Stocks for May 16th

AFCG, FBIO, HRZN
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Negative

FBIO, AFCG and HRZN have been added to the Zacks Rank #5 (Strong Sell) List on May 16, 2025.

image for news New Strong Sell Stocks for May 16th

Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates

FBIO
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative

Fortress Biotech (FBIO) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.03 per share a year ago.

image for news Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

FBIO, FBIOP
Published: March 26, 2025 by: Seeking Alpha
Sentiment: Neutral

Fortress Biotech, Inc. (NASDAQ:FBIO ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - CFO Srinivas Sidgiddi - VP, R&D Louis Donati - Director, Market Access Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - AGP Brandon Folkes - Rodman & Renshaw Jason Wittes - ROTH Capital Kalpit Patel - B. Riley Securities Operator Ladies and gentlemen, thank you for standing by.

image for news Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

About Fortress Biotech, Inc. (FBIO)

IPO Date 2011-11-17
Website https://www.fortressbiotech.com
Industry Biotechnology
CEO Dr. Lindsay Allan Rosenwald
Employees 101

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.